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Abstract
Background: This study was carried out to determine the prognostic significance of preoperative peripheral
epithelial cell adhesion molecule- positive (EpCAM +) circulating tumor cell (CTC) and T regulatory (Treg) cell
levels in hepatocellular carcinoma (HCC) patients for the prediction of postoperative recurrence following curative
resection.
Methods: A total of 49 patients about to undergo curative resection for HCC were recruited into the study. PCR
and FACS were used to detect the preoperative levels of EpCAM mRNA+ CTCs and CD4+CD25+Foxp3+ Treg cells.
The prognostic value of EpCAM mRNA+ CTCs, CD4+CD25+Foxp3+ Treg cells, and other clinicopathological factors
were analyzed by applying the Kaplan–Meier method and the multivariate Cox proportional hazards model.
Results: The number of EpCAM mRNA+ CTCs and Treg/CD4+ cells showed significant correlation as prognostic
factors of postoperative HCC recurrence: EpCAM mRNA+ CTC ≥ 2.22 (P = 0.001) and Treg/CD4+≥ 5.07 (P = 0.045),
with EpCAM mRNA+ CTC ≥ 2.22 (P = 0.003, HR = 6.668) being the most important indicator. Patients with high CTC/
Treg levels showed a significantly higher risk of developing postoperative HCC recurrence than those with low
CTC/Treg levels (66.7 % vs. 10.3 %, P < 0.001). The high CTC/low Treg group also presented higher 1-year recurrence
rates compared with the low CTC/low Treg level group (50.0 % vs. 10.3 %, P = 0.004).
Conclusions: Elevated EpCAM mRNA+ CTC and Treg/CD4+ levels were associated with early recurrence of HCC,
indicative of poor clinical outcome. The combined detection of EpCAM mRNA+ CTC and Treg/CD4+ may therefore
provide a novel prognostic predictor for HCC patients.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignancy worldwide, and is ranked second in
global cancer-related mortality. The high incidence and
poor prognosis of HCC are current focuses of clinical re-
search [1]. The main treatments for HCC include surgi-
cal resection and liver transplantation. However, the
tumor recurrence rate exceeds 70 % after 5 years follow-
ing resection, and recurrence is considered the main
contributor to mortality [2]. Imaging tests and patho-
logical examination are limited in terms of accuracy and
sensitivity, while common serum markers display poor
diagnostic performance [3]. It is therefore critical to find
robust prognostic biomarkers with which to monitor
postoperative recurrence for HCC patients [4].
The progression of a tumor consists of two stages:
growth of the primary tumor and development of
distant metastases. Circulating tumor cells (CTCs)
spread from the primary tumor sites or the metasta-
ses into the peripheral blood supply, and possess
characteristics of stem cells combined with invasive
ability. Distant metastases induced by CTC invasion
are believed to be responsible for the majority cases
of recurrence and cancer-related deaths. Therefore,
isolation and detection of CTCs will help us to
understand the processes of early metastasis and re-
currence, and the aggressiveness of tumors [5].
Epithelial cell adhesion molecule-positive (EpCAM+)
CTCs are a proven independent risk factor for HCC
recurrence in our previous study [6], while immune
suppressive CD4+CD25+ regulatory T cells (Treg) intra-
nuclear expressing Foxp3+ are associated with tumor
immune tolerance and immune escape [7]. Treg cell
proliferation is known to be significantly associated with
tumor invasion and poor prognosis [7], and increased
proportions of Foxp3+ Treg cells were shown to be an
important predictor for the high recurrence and poor
survival rates of HCC patients [8].
The prognostic significance of CTC or Treg cells alone
for HCC recurrence has therefore already been investi-
gated; however, the prognostic value of CTCs in com-
bination with Tregs has not yet been established. The
objective of our study was therefore to determine the
prognostic significance of preoperative EpCAM+ CTCs
and Treg cells population levels for recurrence in HCC
patients following curative resection, and to explore the




From March to June 2012, 49 HCC patients undergoing
curative resection at the Zhongshan Hospital were re-
cruited (36 males and 13 females), with a median age of
50 years (range: 37 to 83). According to Child-Pugh
score criteria, 48 patients were classified as grade A,
and one as grade B. All cases enrolled had to fulfill
the following criteria: (i) Hepatitis B virus-related
HCC with pathological diagnosis; (ii) about to receive
curative resection; (iii) no history of blood transfu-
sion, acquired immunologically mediated disease or
any anti-tumor treatment within the preceding 6 months.
This study adopted the Barcelona Clinic Liver Cancer
(BCLC) staging system and the Edmondson-Steiner grad-
ing system. Fifty healthy volunteers were recruited as the
control group (35 males and 15 females). All patients
provided informed consent before sample collection.
Approval for the use of human subjects was obtained
from the Research Ethics Committee of Zhongshan
Hospital, and informed consent was obtained from each
individual enrolled in this study.
Specimen collection
A peripheral blood sample (6 mL each) was collected
into an EDTA-K2 anticoagulant tube (BD Biosciences,
USA in the morning on the day of surgery before the
operation. Prior to this, the first 6 mL of blood was dis-
carded to avoid epithelial cell contamination. RNA
extraction and reverse transcription were completed
within 8 h following collection (details below). Samples
of cDNA were preserved at −20 °C. All the patients
received curative resection and the common operation
time was about 2–3 h and the average bleeding was
300 ml.
Apparatus and reagents
The monocyte isolation kit used was Ficoll-Paque
Plus (GE Healthcare, USA). CD45 cells were isolated
with RosetteSep Human CD45 Depletion Cocktail
(Stemcell Technologies, Canada). Other equipment
used included the RNA extraction kit, RNeasy Mini
Kit (Qiagen, Germany), the QuantiTect Reverse
Transcription kit, the Human Regulatory T cell
Staining Kit (eBioscience, USA), the LightCycler 480
Real-time PCR system (Roche, Switzerland) and the
FACS Calibur flow cytometry system (BD Biosci-
ences, USA).
EpCAM mRNA+ CTC detection and qRT-PCR
CTC detection was processed by a negative enrich-
ment and quantitative real time polymerase chain re-
action (qRT-PCR) based platform [9]. A peripheral
blood sample was collected for each patient (5 ml).
Target cells were first negative enriched by Rosette-
Sep Human CD45 Depletion Cocktail (StemCell,
Canada), which to remove leukocyte impureness [9].
After enrichment, messenger RNA (mRNA) was ex-
tracted from the target cells with an RNeasy Mini
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Kit and then reverse transcribed into cDNA using
the QuantiTect Reverse Transcri EpCAM ption kit.
All protocols were according to manufacturer’s in-
structions. qRT-PCR analysis of and β-actin (as an
internal control) transcripts were performed using
the Light Cycler 480 platform (Roche Diagnostics,
Germany) with fluorescent Taqman methodology.
PCR reactions were performed using the following
conditions: 2 min at 50 °C and 2 min at 95 °C,
followed by 45 cycles at 95 °C for 30 s and 60 °C for
30 s. Florescent detection was performed at 60 °C, and
three replicates were carried out for each sample.
Invitrogen (nvitrogen, USA) synthesized the primers
and probe segments. The forward primer :5′-
CTCGCGTTCGGGCTTCT-3′, the reverse primer:
5′- TGTAGTTTTCACAGACACATTCTTCCT-3′, and
the probe [6FAM] ACGGCGACTTTTGCCGCAGCT
TA-MRA were used for analysis of EpCAM expression.
The forward primer: 5′-TGGCATTGCCGACAGGAT-3′,
the reverse primer: 5′-CTCAGGAGGAGCAATGAT
CTTGAT-3′, and the probe [6FAM] -ATCACTG
CCCTGGCACCCAGCATA-MRA were used for ana-
lysis of β-actin expression. All primers and probes
were designed and synthesized by the Life Technology
Corporation (Invitrogen, USA).
Gene expression levels were calculated with the fol-
lowing equations:
2−ΔΔCT [ΔCT = Ct (EpCAM) – Ct (β-actin), and
ΔΔCT =ΔCT − Ct(calibrator),
where Ct (calibrator) stands for the mean ΔCT of the
50 healthy volunteers [9, 10].
Detection of lymphocyte subgroups
Two sets of four-color florescent antibody, CD3/
CD8/CD45/CD4 (BD Biosciences) and CD3/CD16+
CD56/CD45/CD19 (BD Biosciences), were added
(20 μl each) into two separate flow cytometry tubes.
The sample (50 μl whole blood each) was added to
each tube, followed by incubation at room
temperature (RT) under darkness for 15 min. After
adding 0.45 ml erythrocytolysin (BD Biosciences),
the solution was incubated for another 10 min. The
solution was then centrifuged for 5 min at
1200 rpm. The supernatant was discarded and the
pellet was washed twice with 2 ml PBS. After
resuspension in 0.4 ml phosphate-buffered saline
(PBS), the sample was loaded for flow cytometry
analysis. Data analyses were performed with Multi-
SET software (BD Biosciences). Measurements included
percentages of B cells (CD19+), T cells (CD3+), CD4+ T
cells, CD8+ T cells and NK cells (CD16+CD56+) and
the ratio of CD4+/CD8+ T cells.
Detection of CD4+CD25+Foxp3+ Tregs
After the addition of 20 μl anti-CD4-FITC/anti-
CD25-APC (eBioscience) and the relevant isotype
control antibody (IgG1 -FITC and IgG1 -APC, re-
spectively; eBioscience) into two separate flow cy-
tometry tubes, 100 μL whole blood sample was
added, followed by incubation at 4 °C for 30 min in
darkness. After the erythrocytolysis step (as above), each
tube was supplemented with 1 ml permeabilization
reagent and incubated at 4 °C for 60 min. After
washing with PBS, 100 μl mouse serum was added to
the solution and the mixture was incubated at RT
under darkness for 15 min. Intracellular antibody
20 μl anti-Foxp3-PE, and isotype control IgG2a-K-PE
(both from eBioscience), were each added, and the
resulting solution was incubated at RT under dark-
ness for another 30 min. After resuspension in PBS,
the sample was loaded for flow cytometry analysis.
Measurements included proportions of CD4+CD25+
Foxp3+ T cells (Tregs) in total lymphocytes, CD8+ T
cells, CD4+ T cells and CD3+ T cells.
Follow-up for HCC recurrence
All patients had postoperative follow-ups [11]. Time to
recurrence (TTR) was defined as the period from curative
excision to diagnosis of HCC recurrence (including
intrahepatic recurrence and extrahepatic metastasis) based
on MRI and serum AFP levels [12, 13]. Early recurrence
was defined as recurrence within 12 months following
excision [14].
Statistical analysis
Prognostic cut-off values were determined using X-
tile 3.6.1 software [15]. All statistical analyses were
performed using SPSS 17.0. Categorical data and
measurement data were assessed with the χ2 test and
the t-test, respectively. Prognostic factors for early re-
currence were evaluated with univariate analysis and
multivariate COX regression analysis. The associations
between TTR and the prognostic factors were
assessed with Kaplan-Meier survival analysis, and the
inter-curve differences were assessed with the log-




The characteristics of the study participants were listed
in Additional file 1: Table S1. The cohorts were well
matched for serum AFP, age, and sex overall. There were
44 (89.8 %) patients with early HCC (BCLC 0-A) and 14
(28.6 %) patients with early recurrence. Majority of pa-
tients had Child-Pugh score A with multiple tumor.
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EpCAM mRNA+ CTCs and Treg/CD4+ cells definition
According to previous studies, the prognostic cut-off value
for HCC recurrence of EpCAMmRNA+ CTCs (2−ΔΔCT) was
2.0 [9]. In our study, the optimal prognostic cut-off values
calculated by X-tile 3.6.1 software for EpCAM mRNA+
CTCs (2−ΔΔCT) and Treg/CD4+ (%) were 2.22 and 5.07,
respectively. The original data of flow cytometry analysis
for Tregs was shown in Additional file 2: Figure S1.
Association of clinical characteristics and pathological
factors with early recurrence
EpCAM mRNA+ CTC (P < 0.001; Fig. 1a) and Treg/CD4+
ratio (P = 0.02; Fig. 1a, Additional file 3: Table S2) was
observed to be significantly higher in the postoperative
recurrence in recurrence group (Table 1). In addition,
Satellite lesion showed inverse correlation with early re-
currence. There was a positive association between vas-
cular invasion and early recurrence in HCC patients
(Table 1).
Association of EpCAM mRNA+ CTCs and Treg/CD4+
cells with clinical characteristics.
Clinical characteristics and associations with
EpCAM mRNA+ CTCs and Treg/CD4+ were analyzed
using the χ 2 test and the t-test for two subgroups
of HCC patients according to the calculated cut-off
values (Tables 2 and 3). Treg/CD4+ ratio was ele-
vated in the EpCAM mRNA+ CTC ≥ 2.22 group (P =
0.026; Table 4, Fig. 2). A rising rate of vascular inva-
sion within the EpCAM mRNA+ CTC ≥ 2.22 group
was also confirmed (P = 0.027, Table 2). Patients
within the Treg/CD4+ ≥ 5.07 % group were more
likely to be younger (age ≤ 50 years old; P = 0.040)
and male (P = 0.046, Table 3), and displayed an
increased number of multiple satellite focuses in
pathological specimens (P = 0.011, Table 3).
Prognostic model for HCC recurrence
Prognostic models for HCC recurrence were determined
with univariate analysis and multivariate Cox analysis.
Univariate analysis revealed significant prognostic factors
for early recurrence in the 49 HCC patient cohort,
including EpCAM mRNA+ CTC ≥ 2.22 (P = 0.001), Treg/
CD4+ ≥ 5.07 (P = 0.045), and satellite lesions (P = 0.004).
Moreover, multivariate Cox analysis revealed that EpCAM
mRNA+ CTC ≥ 2.22 (P = 0.003, HR = 6.668, Table 5) and
satellite lesions (P = 0.019, HR = 5.917, Table 5) were
dependent prognostic factors. Of these three factors,
EpCAM mRNA+ CTC ≥ 2.22 was determined to be the key
prognostic factor (Table 5).
Survival analysis
The 1-year recurrence rates were 12.5 % and 58.8 % in the
EpCAM mRNA+ CTC < 2.22 group and EpCAM mRNA+
CTC ≥ 2.22 group, respectively (P = 0.002; Fig. 3a); and
similarly 22.5 % and 55.6 % in the Treg/CD4+ < 5.07 group
and Treg/CD4+ ≥ 5.07 group, respectively (P = 0.002;
Fig. 3b). Patients were categorized into four groups ac-
cording to their combined levels of EpCAM mRNA+ CTC
and Treg/CD4+: HH group (high CTC and high Treg
levels), HL group (high CTC and low Treg levels), LH
group (low CTC and high Treg levels) and LL group
(low CTC and low Treg levels). There was a statisti-
cally significant difference between the 1-year recur-
rence rates in the HH group and the LL group
(66.7 % vs.10.3 %, P < 0.001; Fig. 3c). The recurrence
rate in the HL group was 46.4 % higher than in the
LL group (50.0 % vs. 10.3 %, P = 0.004; Fig. 3c).
Discussion
Currently, although surgical resection has greatly im-
proved survival rates among HCC patients, HCC
Fig. 1 Expression of EpCAM mRNA+ CTC and Treg/CD4+ in HCC recurrence vs no recurrence group. a, Based on 2−ΔΔCq algorithm transformation,
the relative EpCAM mRNA expression of CTC in HCC patients with or without tumor recurrence after resection. EpCAM mRNA+ CTC showed
significantly higher in recurrence patients (p = 0.001); b, The high ratio of Treg/CD4+ was observed d in recurrence group (p = 0.0197)
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remains one of the leading causes of malignancy-related
mortality worldwide with a prognosis that is still far
from satisfactory, mainly due to increasing post-
operative recurrence [16]. At present, predictions of
recurrence are mainly based on imaging or biomarkers,
which have limits to reflect the dynamic changes in
tumor microenvironment. It was reported that predic-
tions of recurrence and metastasis of HCC are influ-
enced by characteristics of both tumor cells and the
tumor immune microenvironment [17]. In our previous
Table 1 Association of clinical characteristics and pathological
factors with early recurrence
Variables Early recurrence P
No Yes
Age ≤50 15 8 0.365
>50 20 6
Sex male 26 10 0.838
female 9 4
HBsAg Negative 7 2 0.641
Postive 28 12
HBeAg Negative 27 9 0.357
Postive 8 5
HBVDNA <5*102 21 10 0.453
>5*102 14 4
ALT (U/L) ≤40 30 9 0.412
>40 5 5
AFP (ng/ml) ≤400 23 10 0.768
>400 12 4
EpCAM mRNA+ CTC (2-ΔΔCq) Low (<2.22) 28 4 <0.001*
High (≥2.22) 7 10
Treg/CD4+ (%) <5.07 31 9 0.020*
≥5.07 4 5
Child-Pugh stage A 34 14 0.523
B 1 0
Liver cirrhosis No 9 3 0.753
Yes 26 11
Tumor number Single 33 11 0.101
Multiple 2 3
Tumor size (cm) ≤5 21 8 0.854
>5 14 6
Tumor encapsulation Complete 16 5 0.523
None 19 9
Satellite lesion No 34 10 0.007*
Yes 1 4
Vascular invasion No 21 4 0.047*
Yes 14 10
Edmondson stage I-II 22 9 0.925
II-IV 13 5
BCLC stage 0 + A 33 11 0.101
B + C 2 3
Abbreviations: ALT alanine transaminase, HBsAg Hepatitis B surface antigen, AFP
alphafetoprotein, HBeAg Hepatitis B e antigen. p value of < 0.05 was
considered statistically-significant
Table 2 Association of EpCAM+ CTCs with clinical
characteristics
Clinical characteristics CTC (2-ΔΔCq) P
Low (<2.22) High (≥2.22)
Age (y) ≤50 13 10 0.224
>50 19 7
Sex Female 9 4 0.729
Male 23 13
HBsAg Negative 7 2 0.384
Postive 25 15
HBeAg Negative 24 12 0.586
Postive 8 5
HBVDNA <5*102 21 10 0.703
>5*102 11 7
Child-Pugh score A 32 16 0.166
B 0 1
Liver cirrhosis No 8 4 0.909
Yes 24 13
ALT (U/L) ≤40 19 14 0.103
>40 13 3
AFP (ng/ml) ≤400 28 11 0.060
>400 4 6
Tumor number Single 30 4 0.210
Multiple 2 3
Tumor size (cm) ≤5 18 11 0.566
>5 14 6
Tumor encapsulation Complete 15 6 0.436
None 17 11
Satellite lesion No 30 4 0.210
Yes 2 3
Vascular invasion No 20 5 0.027*
Yes 12 12
Edmondson stage I-II 20 11 0.879
II-IV 12 6
BCLC stage 0 + A 30 14 0.210
B + C 2 3
Treg/CD4+ (%) <5.07 29 11 0.026*
≥5.07 3 6
Early recurrence No 28 7 0.001*
Yes 4 10
p value of < 0.05 was considered statistically-significant
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studies, molecular markers expressed on circulating
tumor cells were found to be closely associated with
early diagnosis and early recurrence of HCC [18].
Moreover, CD4+CD25+Foxp3+Tregs are considered as
suppressors in immune surveillance and anti-tumor
immunity, which are also proved associated with HCC
invasiveness [19]. However, no previous publications have
evaluated prognostic performance of circulating tumor
cells and CD4+CD25+Foxp3+Tregs. Here we first detected
the combined effect of circulating tumor cells and its im-
mune environment on hepatocellular carcinoma.
Based on the optimal prognostic cut-off values for
EpCAM mRNA+ CTC (2 − ΔΔCT) of 2.22, and Treg/
CD4+ (%) of 5.07, as calculated using X-tile soft-
ware, we found that the recurrence rate was elevated
in the EpCAM mRNA+ CTC (2 − ΔΔCT) ≥ 2.22 group
(P = 0.001) and the Treg/CD4+ (%) ≥ 5.07 group (P =
0.0029). The vascular invasion rate was also signifi-
cantly higher in the EpCAM mRNA+ CTC ≥ 2.22 group
(P = 0.027), suggesting the occurrence of tumor mi-
croenvironmental changes in early recurrent cases in
addition to pathological changes.
With the expansion of the tumor microenvironment,
tumor cells spread from the primary lesions, thereby
forming circulating tumor cells (CTCs). Thousands of
CTCs are generated each day, but not all CTCs can be-
come “seeds” of metastatic recurrence. Besides environ-
mental factors, the inherent characteristics of CTCs are
also crucial for metastasis [20]. In recent years, with the
introduction of the “tumor stem cell” concept, tumor
stem cells have been shown to exhibit stem cell-like
features including high capacity for self-renewal, differ-
entiation, and the generation of heterogeneous cells, as
well as high resistance to chemotherapy, radiotherapy
and cytotoxic agents, combined with high capacity for






Age (y) ≤50 16 7 0.040*
>50 24 2
Sex Male 13 0 0.046*
Female 27 9
HBsAg Negative 8 1 0.534
Postive 32 8
HBeAg Negative 30 6 0.609
Postive 10 3
HBVDNA <5*102 25 6 0.815
>5*102 15 3
Child-Pugh score A 39 9 0.632
B 1 0
Liver cirrhosis No 10 2 0.861
Yes 30 7
ALT (U/L) ≤75 26 7 0.460
>75 14 2
AFP (ng/ml) ≤400 32 7 0.881
>400 8 2
Tumor number Single 36 8 0.921
Multiple 4 1
Tumor size (cm) ≤5 25 4 0.319
>5 15 5
Tumor encapsulation Complete 17 4 0.915
None 23 5
Satellite lesion No 38 6 0.011*
Yes 2 3
Vascular invasion No 22 3 0.240
Yes 18 6
Edmondson stage I-II 25 6 0.815
II-IV 15 3
BCLC stage 0 + A 37 7 0.187
B + C 3 2
p value of < 0.05 was considered statistically-significant
Table 4 Association between EpCAM+ CTC and Treg/CD4+
EpCAM mRNA + CTC(2-ΔΔCT) P
Low (<2.22) High (≥2.22)
Treg/CD4+ (%) <5.07 29 11 0.026*
>5.07 3 6
p value of < 0.05 was considered statistically-significant
Fig. 2 Association between EpCAM+ CTC and Treg/CD4+ ratio.
Distribution of Treg/CD4+ ratio in EpCAM mRNA+ -positive and
negative group. The cutoff to discriminate between CTC-positive
and -negative was set at 2.0 [9]
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oncogenesis and tumor maintenance. There is sufficient
evidence that a high ratio of tumor stem cell-like
cells indicates a poor prognosis [21]. Sun et al. re-
ported that EpCAM mRNA+ CTCs retaining stem cell-
like characteristics are “high-quality seeds” for metastasis,
and that the level of EpCAM mRNA+ CTCs is an ideal
predictor for postoperative early recurrence and prognosis
of HCC [22].
Tumor-related immune suppression is mediated
mainly by increased TGF-β secretion or direct Treg cell
infiltration [23]. A recent study [24] found an association
between intratumoral or peripheral blood Tregs and
tumor invasion. Tregs mediate tumor immune escape
and promote tumor growth mainly by suppressing
tumor immune effector cells (especially cytotoxic lym-
phocytes), or by inducing effector T cell tolerance to
tumor antigens. The resulting imbalance between
intratumoral Tregs and cytotoxic T cells was shown to
be an effective prognostic predictor. In our study, a
significant correlation was observed between the levels
of EpCAM mRNA+ CTC and peripheral Treg/CD4+, with
an increasing trend (P = 0.026). This result may sup-
ported that Tregs contributed as “soil” which may
change the tumor microenvironment to help CTCs get
out of immune clearance by cytotoxic T cells as well as
colonization in HCC patients.
The results of univariate Cox analysis found that the
significant prognostic factors for early recurrence
included EpCAM mRNA+ CTC ≥ 2.22 (P = 0.001) and
Treg/CD4 + ≥ 5.07 (P = 0.045). Further multivariate Cox
analysis revealed EpCAM mRNA+ CTC ≥ 2.22 (P = 0.003,
HR = 6.668) to be a significant and independent prog-
nostic biomarker for early recurrence, in accordance
with the study by Sun et al., which reported EpCAM
mRNA+ CTC ≥ 2 to be an independent predictor for
early HCC recurrence (within 1 year following resec-
tion) [13]. Survival curve analyses found that the early
recurrence rates within the EpCAM mRNA+ CTC ≥
2.22 group (12.5 % vs. 58.8 %, P = 0.002, Fig. 3a) and
Treg/CD4+ ≥ 5.07 group (22.5 % vs. 55.6 %, P = 0.038,
Fig. 3b) were markedly elevated. Combining these two
factors of “soil” and “seeds”, we found that the early
recurrence rate in the group with combined high
CTC and high Treg levels was significantly higher
than in the combined low CTC and low Treg group
(66.7 % vs. 10.3 %, P < 0.001, Fig. 3c), while the recur-
rence rate within the combined high CTC and low
Treg group was 46.4 % higher than for the combined
low CTC and low Treg group (50.0 % vs. 10.3 %, P =
0.004, Fig. 3c). These results also implied that ele-
vated Tregs cells could cause immune suppression,
and contribute CTCs escape from peripheral immune
clearance. Consequently, the spread of CTCs lead to
HCC metastasis and recurrence. However, the mech-
anisms of EpCAM mRNA+ CTC and Treg cells
interaction remain unclear, warranting future larger
clinical studies as well as further basic explorative
research.
The limitations of the current study were a small co-
hort size, short follow-up time, and only patients with
Table 5 Analyses of risk factors for HCC recurrence
Univariate analysis Multivariate analysis
HR (95 % CI) P HR (95 % CI) P
Age (>50y vs. ≤ 50y) 0.626 (0.217–1.804) 0.385 N.A.
Gender (Male vs. Female) 0.886 (0.278–2.827) 0.838 N.A.
HBsAg (Positive vs. Negative) 1.433 (0.321–6.406) 0.638 N.A.
Cirrhosis (Positive vs. Negative) 1.323 (0.369–4.743) 0.668 N.A.
Child-Pugh grade (B vs. A) 0.048 (0.000–23944) 0.700 N.A.
ALT (>40 U/L vs. ≤ 40 U/L) 0.783 (0.246–2.497) 0.679 N.A.
AFP (>400 ng/ml vs. ≤ 400 ng/ml) 2.258 (0.756–6.743) 0.145 N.A.
Tumor number (multiple vs. one) 3.570 (0.998–12.896) 0.052 N.A.
Tumor size (>5 cm vs. ≤5 cm) 1.094 (0.379–3.154) 0.868 N.A.
Tumor encapsulation (Yes vs. No) 1.425 (0.477–4.252) 0.526 N.A.
Satellite lesion (Yes vs. No) 5.726 (1.771–18.509) 0.004 5.917 (1.342–26.078) 0.019
Vascular invasion (Yes vs. No) 2.943 (0.922–9.399) 0.068 N.A.
Edmondson classification (III-IV vs. I-II) 1.057 (0.354–3.155) 0.921 N.A.
BCLC stage (B + C vs. 0 + A) 3.496 (0.966–12.646) 0.056 N.A.
EpCAM+ CTC 2-ΔΔCq (≥2.22 vs. < 2.22) 6.580 (2.056–21.055) 0.001 6.668 (1.943–22.883) 0.003
Treg/CD4+(≥5.07 vs. < 5.07) 2.993 (0.998–8.947) 0.045 0.825 (0.196–3.468) 0.792
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Hepatitis-B induced HCC and early stages (BCLC 0 and
A) have been included in this study, which may results
the clinical significance of Edmondson classification
and AFP in HCC were not be observed. These limita-
tions will be addressed in our next step clinical
investigation.
Conclusions
In summary, our study found an association between
peripheral blood EpCAM mRNA+ CTC and CD4+CD25
+Foxp3+ Treg preoperative levels with postoperative re-
currence and metastasis in HCC patients. Combined
measurement of both cell types may improve prognostic
efficacy. We are currently carrying out a large prospect-
ive randomized controlled trial to further confirm the
value of this combined measurement in predicting HCC
recurrence and prognosis.
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Treg/CD4+(≥5.07 %), high EpCAM mRNA+ CTC(<2.22) and low Treg/CD4+(<5.07 %), low/no EpCAM mRNA+ CTC (<2.22) and high Treg/CD4+(≥5.07 %), and
low/no EpCAM mRNA+ CTC (<2.22) and low Treg/CD4+(<5.07 %)
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